Axis-Shield Axis-Shield and Bio-Rad Sign Agreement for Commercialization of Sepsis Biomarker Premium Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide. Bio-Rad Takes Option to Commercialize Axis-Shield's HBP Sepsis Marker Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed. FDA Clears Rheumatoid Dx Test by Bio-Rad, Axis-Shield With FDA clearance, the test, which had been available outside the US, will now become available in the US. Breaking News Pacific Biosciences Acquires Sample Preparation Firm Circulomics Bruker Posts 34 Percent Jump in Q2 Revenues GenomeWeb Index Gains Slightly in July as Fluidigm, PerkinElmer, Bio-Rad Post Strong Increases Feinstein Institutes for Medical Research Wins $2.9M NIH Grant to Study Polygenic Embryo Screening Top Five Articles on GenomeWeb Last Week: CDC, Bio-Rad, 10x Genomics, PerkinElmer, and More InterVenn Biosciences Closes $201M Series C Round The Scan And Back The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database. Lacks Family Hires Attorney A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports. For the Unknown The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona. PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.